About Autobahn Therapeutics
Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neuroimmunologic clinical candidates leveraging its brain-targeting chemistry platform. Autobahn aims to unlock new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. The company’s pipeline is led by ABX-002, a thyroid hormone receptor beta agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression. Autobahn Therapeutics is based in San Diego.
Company details
Funding
Total raised
$228M
Last stage
Series C
Investors
Founders
Tom Scanlan
Researcher at OHSU whose lab originated Autobahn Therapeutics; developed brain-penetrating thyroid hormone receptor beta agonist molecules for CNS diseases.
Keith Lenden
Co-founded Autobahn Therapeutics alongside Tom Scanlan; listed as Founder and President by CB Insights.
LinkedInKevin Finney
Experienced biopharma executive; former President & COO of Abide Therapeutics and co-founder of Zavante Therapeutics. Leads Autobahn as President and Chief Executive Officer.
LinkedInThomas Scanlan
Co-founder of Autobahn Therapeutics and Professor of Chemical Physiology and Biochemistry at Oregon Health & Science University (OHSU); scientific expert in thyromimetics underpinning the company's TRβ agonist platform.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.